Detalhe da pesquisa
1.
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Blood
; 139(9): 1289-1301, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521108
2.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med
; 373(11): 1040-7, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352815
3.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
JCI Insight
; 3(8)2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669947
4.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med
; 21(8): 914-921, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26193344
5.
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Clin Cancer Res
; 20(5): 1355-65, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24520093
6.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
JCI Insight
; 4(4)2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830874
7.
Preliminary evaluation of the Health Background Questionnaire for Pain and clinical encounter form for pain.
Pain Med
; 6(6): 443-51, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16336481